ONX-0914, a selective inhibitor of immunoproteasome, ameliorates experimental autoimmune myasthenia gravis by modulating humoral response
Journal of Neuroimmunology Aug 31, 2017
Liu RT, et al. – The effects of the selective immunoproteasome inhibitor, ONX–0914, were inspected on experimental autoimmune myasthenia gravis (EAMG). Based on the data obtained, ONX-0914 appeared to bring benefit for MG (myasthenia gravis) therapy.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
